Viewing Study NCT05782361

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:51 AM
Ignite Modification Date: 2025-12-31 @ 6:24 AM
Study NCT ID: NCT05782361
Status: RECRUITING
Last Update Posted: 2025-08-20
First Post: 2023-01-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Sponsor: Institute of Cancer Research, United Kingdom
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Cancer View
None Non Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None tepotinib View
None pembrolizumab View
None lung cancer View
None MET inhibition View
None immunotherapy View